Skip to main content

Table 4 Adverse events in the study patients (n = 89)

From: Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy

EventNo. of patients (%)
Constipation12 (13.5)
Local reaction2 (2.2)
Pruritus2 (2.2)
Flu-like symptoms2 (2.2)
Abdominal cramps1 (1.1)
Transient skin rash1 (1.1)
Bloating1 (1.1)
Meteorism1 (1.1)
Nausea1 (1.1)
Transient vaginal spotting1 (1.1)
Urticariaa1 (1.1)
Vertigo1 (1.1)
Allergic reactionb1 (1.1)
Serious adverse events1 (1.1)
Adverse events leading to treatment discontinuation1 (1.1)
Total20 (22.5)
  1. aExacerbation of previous disease
  2. bleading to treatment discontinuation
\